In conclusion, this study provides additional evidence that both CP and PCP are safe and efficient techniques for achieving a steady 30% reduction of IOP in patients with POAG and PEG, up to 48 months for CP and 42 months for PCP. This evidence concerns the gene CP and open-angle glaucoma.